How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

994 results for

Lymphoid Hyperplasia

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Zydelig - idelalisib

Investigational New Drug (Application) iNHL indolent non-Hodgkin lymphoma IRC independent review committee ITT intent-to-treat KM Kaplan-Meier LDH lactate dehydrogenase LPL lymphoplasmacytic lymphoma m module mAb monoclonal antibody MALT mucosa-associated lymphoid tissue MCL mantle cell lymphoma MedDRA Medical Dictionary for Regulatory Activities MID minimally important difference MM multiple myeloma MR minor response MRI magnetic resonance imaging MST medical search term MZL marginal zone lymphoma N or n (...) this approach is limited especially with respect to MZL and LPL/WM. In resistant and refractory stages the current treatment alternatives are very limited and often carry significant toxicities. About the product Idelalisib inhibits phosphatidylinositol 3 kinase p110d (PI3Kd), which is hyperactive in B cell malignancies and is central to multiple signalling pathways that drive proliferation, survival, homing, and retention of malignant cells in lymphoid tissues and bone marrow. Idelalisib is a selective

2014 European Medicines Agency - EPARs

163. Mekinist - trametin

, GI damage, lymphoid organ depletion, bone marrow cellularity ?, labored breathing, killed in moribund condition, F: red blood cell parameters ? bw=body weight; M=male; F=female; GI=gastrointestinal; Hb=haemoglobin; WBC=white blood cells; P=serum inorganic phosphorus; ALP=alkaline phosphatase CHMP assessment report EMA/CHMP/675236/2013 Page 26/132 Repeat dose toxicity Table 2: Repeat-dose toxicity studies with trametinib Study ID Species/Sex/ Number/Group Dose/Route mg/kg/day Duration NOEL/ NOAEL (...) showed that trametinib was a skin sensitiser. Regarding the immunotoxicity of trametinib, in the repeated dose toxicity studies done on rats with a daily oral dosing for up to 13 weeks, it was shown that the principal immune-related adverse effect was bone marrow degeneration/necrosis and lymphoid necrosis in lymph nodes, spleen and thymus. In addition, adverse skin and gastric changes were associated with inflammation, characterized by increased cellularity (lymphocytes and plasma cells) in lymph

2014 European Medicines Agency - EPARs

166. Entyvio - vedolizumab

-linked immunosorbent assay ET early Termination FP Finished Product GALT gut-associated lymphoid tissue GI gastrointestinal GLP good laboratory practice GPI generic product identifier HAHA human anti-human antibodies HBI Harvey Bradshaw Index HBV hepatitis B virus Entyvio Assessment report EMA/CHMP/676643/2013 Page 5/166 HCV hepatitis C virus HIV human immunodeficiency virus HLT high level term HPLC High Performance Liquid Chromatography HRQOL health-related quality of life HRP horseradish Peroxidase (...) -02 and MLN02 MS multiple sclerosis N/A not applicable NC negative Control NEC not elsewhere classified ND not determined nHAHA neutralising HAHA NHP non-human primate NK natural killer NMSC Non-Melanoma Skin Cancer NOAEL no observed adverse effect level NOR Normal Operating Ranges NSAID nonsteroidal anti-inflammatory drug OD Optical Density PAHA primate antihuman antibodies Ph. Eur. European Pharmacopoeia PALS Periarteriolar lymphoid sheaths PASS Post Authorisation Safety Study PBMC Peripheral

2014 European Medicines Agency - EPARs

169. Antibody-Mediated Rejection in Cardiac Transplantation: Emerging Knowledge in Diagnosis and Management Full Text available with Trip Pro

of heart transplantation, the heart transplant community has typically taken its lead from experience in renal transplantation, adapting therapies that were originally designed to treat hematologic diseases, malignancies, and autoimmune disorders. , Broadly speaking, the underlying mechanisms for these therapies are based on the following: (1) Suppression of the T-cell response (eg, corticosteroids, mycophenolate mofetil (MMF), anti-lymphocyte antibodies, photopheresis, or total lymphoid irradiation

2015 American Heart Association

171. Primary Sclerosing Cholangitis

American Journal of GASTROENTEROLOGY www.amjgastro.com 656 VOLUME 110 | MAY 2015 Lindor et al. 18. G ra n t A J , G o dda r d S , Ahmed-Cho udh u r y J et al. H epa tic exp r essio n o f secondary lymphoid chemokine (CCL21) promotes the development of portal-associated lymphoid tissue in chronic infl ammatory liver disease . Am J P a t h o l 2002 ; 160 : 1445 – 55 . 19. P o l S , Ro ma na CA , Ric h a r d S et al. M icr osp o r idia inf ec tio n in pa tien ts with the human immunodefi ciency virus

2015 American College of Gastroenterology

172. Diagnosis and Management of Aplastic Anaemia

; sometimes hypocellularity is patchy with both hypocellular and residual cellular areas. Focal hyperplasia of erythroid or granulocytic cells at a similar stage of maturation may be observed. Small lymphoid aggregates may occur, particularly in the acute phase of the disease or when AA is associated with systemic autoimmune diseases, such as rheumatoid arthritis or systemic lupus erythematosus. Increased reticulin staining, dysplastic megakaryocytes (best assessed by immunohistochemistry) and blasts (...) with pancytopenia and a patchy hypocellular bone marrow with limited areas of lymphoid infiltration that can easily be missed in small samples. The bone marrow biopsy should be examined carefully for foci of lymphoma cells or fibrosis, which may be seen in only a small part of the specimen. Lymphocytes are often prominent in AA and immunophenotypic marker studies and gene rearrangement studies will help to exclude a diagnosis of lymphoma. Additional features, such as splenomegaly, make AA very unlikely Primary

2015 British Committee for Standards in Haematology

175. Xeljanz (tofacitinib citrate)

in this study. 32 lymphoproliferative disorder (PTLD) resulting from immunosuppression. It has been discussed that the T-cell lymphoma was attributed to a higher sensitivity of T-cells that regulate lymphoma development to tofacitinib in monkeys. Furthermore, lymphoid (follicular) hyperplasia in the lymph nodes and spleen were observed at all dose levels. This was B cell hyperplasia, but was negative for LCV. Thus, this lymphocyte hyperplasia was not considered a precursor of B-cell lymphoma. The NOAEL (...) conducted. In both animal species, decreases in circulating lymphocytes, NK cells, and T cells and lymphoid depletion in lymphoid tissues, which were considered attributable to JAK1/3 inhibition by tofacitinib, and decreases in red blood cell parameters and the percent reticulocytes, which were considered attributable to JAK2 inhibition by tofacitinib, were observed. In the monkey 39-week oral study, lymphomas, which were considered associated with immunosuppression, and lymphoid (follicular

2013 Pharmaceuticals and Medical Devices Agency, Japan

176. Alabel/Alaglio (aminolevulinic acid hydrochloride)

dose toxicity studies in rats (4 and 13 weeks) and dogs (4 weeks). The major target organ was the liver (particularly bile duct), and major findings included increased aspartate aminotransferase (AST), alanine aminotransferase (ALT) and total bilirubin, and brown pigmentation in the liver. Furthermore, in rats, mild anemia, hepatic necrosis, bile duct hyperplasia, peribiliary infiltration, reddish brown urine, brown pigmentation in the kidney, and proximal tubule epithelial vacuolation were also (...) -brown liver and kidney, increases in liver and kidney weights, focal hepatocellular necrosis or unicellular necrosis, bile duct hyperplasia, and proximal tubule epithelial vacuolation were noted. In the =366 mg/kg/day groups, ear or tail flushing and excoriation, which were probably due to the phototoxicity of PPIX, decreased hematocrit, increases in neutrophil proportion and white blood cell count, increases in ALP , blood urea nitrogen, total bilirubin and triglyceride, decreased creatinine

2013 Pharmaceuticals and Medical Devices Agency, Japan

178. Methotrexate-associated Lymphoproliferative Disorders in Patients With Rheumatoid Arthritis: Clinicopathologic Features and Prognostic Factors. (Abstract)

of MTX-LPD. Paraffin-embedded tissue samples of 219 patients with MTX-LPD were analyzed. In total, 30,33,106, and 26 had reactive lymphoid hyperplasia (RH), polymorphic-LPD (Poly-LPD), diffuse large B-cell lymphomas (DLBCLs), and classic Hodgkin lymphoma (CHL), respectively. The clinicopathologic features of RH, Poly-LPD, DLBCLs, and CHL were as follows: extranodal involvement: 13.8% (4/29), 36.4% (12/33), 69.5% (73/105), and 15.4% (4/26); Epstein-Barr virus encoded RNA positivity: 55.2% (16/29

2019 American Journal of Surgical Pathology

179. 18F-FDG PET/CT for staging and response assessment of primary parotid MALT lymphoma with multiple sites involvement: A case report. Full Text available with Trip Pro

and response assessment of primary parotid MALT lymphoma with multiple sites involvement. As far as we know, there are no similar case reports have been published before.A 71-year-old woman, who received mass resection twice during the past 2 years due to the repeatedly relapse of facial painless masses and diagnosed as reactive lymphoid hyperplasia by pathologic tests. However, the pathological diagnosis was then changed to primary parotid MALT lymphoma after left parotidectomy operation because of a new (...) 18F-FDG PET/CT for staging and response assessment of primary parotid MALT lymphoma with multiple sites involvement: A case report. Mucosa-associated lymphoid tissue (MALT) lymphoma is an extranodal low-grade B cell lymphoma that generally exhibits an indolent clinical course. Currently, the application of F-fluorodeoxyglucose positron emission tomography/computed tomography (F-FDG PET/CT) in MALT lymphoma is still controversial. Herein, we reported a case of using F-FDG PET/CT for staging

2019 Medicine

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>